Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · IEX Real-Time Price · USD
11.59
+0.14 (1.22%)
At close: May 1, 2024, 4:00 PM
12.05
+0.46 (3.97%)
After-hours: May 1, 2024, 5:06 PM EDT
Inovio Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for INO stock have an average target of 21, with a low estimate of 11 and a high estimate of 40. The average target predicts an increase of 81.19% from the current stock price of 11.59.
Analyst Consensus: Buy
* Price targets were last updated on Mar 8, 2024.
Analyst Ratings
The average analyst rating for INO stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 2 | 2 | 2 | 2 |
| Hold | 3 | 3 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $40 | Buy | Maintains | $40 | +245.13% | Mar 8, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $11 | Hold | Reiterates | $11 | -5.09% | Mar 7, 2024 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $4 | Hold → Buy | Upgrades | $4 | -65.49% | Jan 25, 2024 |
| JMP Securities | JMP Securities | Buy Initiates $12 | Buy | Initiates | $12 | +3.54% | Jan 4, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $24 | Hold | Reiterates | $24 | +107.08% | May 11, 2023 |
Financial Forecast
Revenue This Year
610.24K
from 832.01K
Decreased by -26.65%
Revenue Next Year
7.10M
from 610.24K
Increased by 1,062.65%
EPS This Year
-3.97
from -6.09
EPS Next Year
-3.42
from -3.97
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.1M | 17.9M | 250.3M | 254.6M | 2.7M |
| Avg | 610,242 | 7.1M | 158.9M | 122.6M | 2.6M |
| Low | n/a | n/a | 74.7M | 294,000 | 2.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 26.2% | 2,839.3% | 3,427.8% | 60.2% | -97.8% |
| Avg | -26.7% | 1,062.7% | 2,139.5% | -22.8% | -97.9% |
| Low | - | - | 953.1% | -99.8% | -97.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -3.36 | -2.99 | 0.90 | 0.17 |
| Avg | -3.97 | -3.42 | 0.13 | 0.16 |
| Low | -4.55 | -4.32 | -0.60 | 0.16 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | 33.1% |
| Avg | - | - | - | 28.0% |
| Low | - | - | - | 24.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.